QSAM Biosciences EV/EBIT
Was ist das EV/EBIT von QSAM Biosciences?
EV/EBIT von QSAM Biosciences, Inc. ist N/A
Was ist die Definition von EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT von Unternehmen in Health Care Sektor auf OTC im Vergleich zu QSAM Biosciences
Was macht QSAM Biosciences?
QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.
Unternehmen mit ev/ebit ähnlich QSAM Biosciences
- Zacapa Resources Ltd hat EV/EBIT von N/A
- Dxi Capital Corp hat EV/EBIT von N/A
- African Gold hat EV/EBIT von N/A
- Contact Gold hat EV/EBIT von N/A
- CarParts.com Inc hat EV/EBIT von N/A
- Cel-Sci hat EV/EBIT von N/A
- QSAM Biosciences hat EV/EBIT von N/A
- Nephros hat EV/EBIT von N/A
- Nephros hat EV/EBIT von N/A
- Nephros hat EV/EBIT von N/A
- Nephros hat EV/EBIT von N/A
- Homerun Resources hat EV/EBIT von N/A
- DelMar Pharmaceuticals hat EV/EBIT von N/A